Mechanisms, function and clinical applications of DNp73

被引：30

作者：

Di, Cuixia ^{[1
,3
,4
]}

Yang, Lina ^{[2
]}

Zhang, Hong ^{[1
,3
,4
]}

Ma, Xiaofei ^{[1
,3
,4
]}

Zhang, Xin ^{[1
,3
,4
]}

Sun, Chao ^{[1
,3
,4
]}

Li, Hongyan ^{[1
,3
,4
]}

Xu, Shuai ^{[1
,3
,4
]}

An, Lizhe ^{[2
]}

Li, Xun ^{[5
]}

Bai, Zhongtian ^{[5
]}

机构：

[1] Chinese Acad Sci, Inst Modern Phys, Dept Heavy Ion Radiat Med, Lanzhou, Peoples R China

[2] Lanzhou Univ, Sch Life Sci, Lanzhou 730000, Peoples R China

[3] Chinese Acad Sci, Key Lab Heavy Ion Radiat Biol & Med, Lanzhou, Peoples R China

[4] Key Lab Heavy Ion Radiat Med Gansu Prov, Lanzhou, Peoples R China

[5] Lanzhou Univ, Hosp 1, Dept Gen Surg 2, Lanzhou 730000, Peoples R China

来源：

CELL CYCLE | 2013年 / 12卷 / 12期

基金：

中国国家自然科学基金;

关键词：

DNp73; alternative splicing; apoptosis; cancer; chemosensitivity; radiotherapy; tumorigenesis; CERVICAL-CANCER CELLS; P53; FAMILY; TUMOR-SUPPRESSOR; DNA-DAMAGE; DELTA-NP73; EXPRESSION; NEURONAL SURVIVAL; PROGNOSTIC VALUE; P73; POOR-PROGNOSIS; OVARIAN-CANCER;

D O I：

10.4161/cc.24967

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

p73, has two distinct promoters, which allow the formation of two protein isoforms: full-length transactivating (TA) p73 and an N-terminally truncated p73 species (referred to as DNp73) that lacks the N-terminal transactivating domain. Although the exact cellular function of DNp73 is unclear, the high expression levels of the genes have been observed in a variety of human cancers and cancer cell lines and have been connected to pro-tumor activities. Hence the aim of this review is to summarize DNp73 expression status in cancer in the current literature. Furthermore, we also focused on recent findings of DNp73 related to the biological functions from apoptosis, chemosensitivity, radiosensitibity, differentiation, development, etc. Thus this review highlights the significance of DNp73 as a marker for disease severity in patients and as target for cancer therapy.

引用

页码：1861 / 1867

页数：7

共 90 条

[1] E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry [J].

Alla, Vijay ;

Kowtharapu, Bhavani S. ;

Engelmann, David ;

Emmrich, Stephan ;

Schmitz, Ulf ;

Steder, Marc ;

Puetzer, Brigitte M. .

CELL CYCLE, 2012, 11 (16) :3067-3078

[2] p63/p73 in the control of cell cycle and cell death [J].

Allocati, N. ;

Di Ilio, C. ;

De Laurenzi, V. .

EXPERIMENTAL CELL RESEARCH, 2012, 318 (11) :1285-1290

[3] Family friction as ΔNp73 antagonises p73 and p53 [J].

Bailey, Sarah G. ;

Cragg, Mark S. ;

Townsend, Paul A. .

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2011, 43 (04) :482-486

[4] ΔNp73ss is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria [J].

Bantel, Heike ;

Simon, Hans-Uwe .

CELL CYCLE, 2010, 9 (14) :2710-2711

[5]

Becker K, 2006, INT J ONCOL, V29, P889

[6] DNp73α protects myogenic cells from apoptosis [J].

Belloni, L. ;

Moretti, F. ;

Merlo, P. ;

Damalas, A. ;

Costanzo, A. ;

Blandino, G. ;

Levrero, M. .

ONCOGENE, 2006, 25 (25) :3606-3612

[7] Roles for p53 and p73 during oligodendrocyte development [J].

Billon, N ;

Terrinoni, A ;

Jolicoeur, C ;

McCarthy, A ;

Richardson, WD ;

Melino, G ;

Raff, M .

DEVELOPMENT, 2004, 131 (06) :1211-1220

[8]

Blandino G, 2004, CELL CYCLE, V3, P886

[9] DNp73 a matter of cancer:: Mechanisms and clinical implications [J].

Buhlmann, Sven ;

Puetzer, Brigitte M. .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2008, 1785 (02) :207-216

[10] p53 family members in myogenic differentiation and rhabdomyosarcoma development [J].

Cam, Hakan ;

Griesmann, Heidi ;

Beitzinger, Michaela ;

Hofmann, Lars ;

Beinoraviciute-Kellner, Rasa ;

Sauer, Markus ;

Huettinger-Kirchhof, Nicole ;

Oswald, Claudia ;

Friedl, Peter ;

Gattenloehner, Stefan ;

Burek, Christof ;

Rosenwald, Andreas ;

Stiewe, Thorsten .

CANCER CELL, 2006, 10 (04) :281-293

← 1 2 3 4 5 6 7 8 9 →